Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Niagen Bioscience Inc (NAGE)

Niagen Bioscience Inc (NAGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 403,020
  • Shares Outstanding, K 79,806
  • Annual Sales, $ 99,600 K
  • Annual Income, $ 8,550 K
  • EBIT $ 19 M
  • EBITDA $ 20 M
  • 60-Month Beta 2.35
  • Price/Sales 3.38
  • Price/Cash Flow 85.38
  • Price/Book 5.70

Options Overview Details

View History
  • Implied Volatility 317.41% (+27.08%)
  • Historical Volatility 44.50%
  • IV Percentile 99%
  • IV Rank 35.91%
  • IV High 789.28% on 02/18/26
  • IV Low 53.07% on 06/27/25
  • Expected Move (DTE 18) 0.85 (17.03%)
  • Put/Call Vol Ratio 0.18
  • Today's Volume 388
  • Volume Avg (30-Day) 278
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 11,482
  • Open Int (30-Day) 13,830
  • Expected Range 4.14 to 5.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.01
  • Number of Estimates 2
  • High Estimate 0.02
  • Low Estimate 0.01
  • Prior Year 0.03
  • Growth Rate Est. (year over year) -66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.74 +5.34%
on 02/23/26
6.10 -18.20%
on 02/03/26
-1.10 (-18.06%)
since 02/02/26
3-Month
4.74 +5.34%
on 02/23/26
7.05 -29.27%
on 12/22/25
-1.41 (-22.03%)
since 12/02/25
52-Week
4.74 +5.34%
on 02/23/26
14.69 -66.03%
on 06/30/25
-0.65 (-11.52%)
since 02/28/25

Most Recent Stories

More News
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction

Divestiture streamlines operations and advances the Company’s strategy to fully exit non-core activities

NAGE : 4.99 (-1.19%)
Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®

Patent strengthens Niagen Bioscience’s intellectual property moat in fast-growing NAD+-boosting IV and injectable delivery formats, supporting commercial expansion and deterring infringers

NAGE : 4.99 (-1.19%)
Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen

Taking place March 23-25, 2026, this three-day scientific forum will convene the world’s foremost NAD experts in Copenhagen to advance evidence-based dialogue and accelerate clinical translation

NAGE : 4.99 (-1.19%)
Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call...

NAGE : 4.99 (-1.19%)
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*

Qualified Customers may now purchase Tru Niagen at www.truniagen.com using HSA/FSA funds with a Truemed Letter of Medical Necessity (LMN)

NAGE : 4.99 (-1.19%)
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast

This acquisition establishes Niagen Bioscience as the sole owner of the most comprehensive and defensible intellectual property portfolio in the NAD+ industry

NAGE : 4.99 (-1.19%)
Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)

This science-backed blend of Niagen and clinically studied actives is designed to support healthy skin, hair, and nails

NAGE : 4.99 (-1.19%)
Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID

Findings show a significant increase in NAD+ levels and within-group benefits in fatigue, depression, and sleep quality

NAGE : 4.99 (-1.19%)
Niagen Bioscience Announces $10 Million Share Repurchase Program

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors...

NAGE : 4.99 (-1.19%)
Niagen Bioscience: Q3 Earnings Snapshot

Niagen Bioscience: Q3 Earnings Snapshot

NAGE : 4.99 (-1.19%)

Business Summary

Niagen Bioscience Inc. is a nicotinamide adenine dinucleotide science and healthy-aging research company. Niagen Bioscience Inc., formerly known as ChromaDex Corp., is based in LOS ANGELES.

See More

Key Turning Points

3rd Resistance Point 5.26
2nd Resistance Point 5.19
1st Resistance Point 5.09
Last Price 4.99
1st Support Level 4.91
2nd Support Level 4.84
3rd Support Level 4.74

See More

52-Week High 14.69
Fibonacci 61.8% 10.89
Fibonacci 50% 9.71
Fibonacci 38.2% 8.54
Last Price 4.99
52-Week Low 4.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar